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Abstract
Background: Paget’s disease is a rare skin disorder occurring in the breast (mammary) or in the groin, genital, peri-
anal and axillary regions (extra-mammary). Typical treatment involves surgical excision, which in the case of extra-
mammary Paget’s disease, can lead to significant morbidity. Photodynamic therapy (PDT) which uses a topical or
intravenous photosensitizing agent that is activated by a light source to ablate abnormal tissue, offers a minimally
invasive alternative. The purpose of this study was to assess the effectiveness of photodynamic therapy in the
treatment of Paget’s disease.
Methods: Following Cochrane guidelines, a comprehensive systematic review of all clinical studies and reports
examining the use of PDT for mammary and extra-mammary Paget’s disease was conducted. Study quality was
assessed using the Oxford Levels of Evidence Scale.
Results: 21 retrospective and 2 prospective non-comparative studies were identified and included in the review: 9
case reports with 1-2 patients and 14 case series with 1-16 patients. These reports totalled 99 patients with 133
extra-mammary Paget’s lesions and 3 patients (with 3 lesions) with mammary Paget’s disease. Follow-up periods
were typically one year or less, with 77/133 extra-mammary lesions exhibiting complete response to PDT. One
recurrent mammary skin lesion and two mammary lesions treated concomitantly with surgery also exhibited
complete responses.
Conclusions: Evidence of the effectiveness of PDT for Paget’s disease is promising, but limited. This may, in part,
be explained by the rarity of the condition, making controlled comparative clinical trials challenging.
Background
Paget’s disease is an extremely rare form of intraepithe-
lial adenocarcinoma that may have an underlying
tumour component. It primarily affects Caucasian
women over the age of 50[1]. Since in its early stages
symptoms are often minor, individuals may not seek
medical attention for several years, delaying diagnosis
and treatment[1-3]. In addition, the condition can be
misdiagnosed as eczema or dermatitis,[4] with a benign
dermatologic diagnosis creating further delays[5].
Paget’s disease is categorized as either mammary or
extra-mammary. While the two types are histologically
the same (the epidermis shows diffuse infiltration of
large vacuolated cells with a bluish cytoplasm (Paget
cells)), the location differs[6]. Mammary Paget’s disease
involves the skin of the breast, in or around the nipple.
Most individuals with the condition (> 92%) have under-
lying breast cancer (either ductal carcinoma in situ or
invasive breast cancer)[2,7]. Extra-mammary Paget’sd i s -
ease mainly affects the perianal and genital areas, or
elsewhere on the skin near apocrine glands,[6] and is
extremely rare (only a few hundred reports have been
documented in peer-reviewed literature)[6]. In many
patients, the disease may exist for 10 to 15 years without
progressing. Unlike mammary Paget’s, a smaller propor-
tion of cases exhibit an underlying neoplastic compo-
nent (approximately 25% have carcinoma of the
Bartholin glands, urethra, bladder, vagina, cervix, endo-
metrium, prostate, rectum, or colon)[6].
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ever, this can lead to significant morbidity, especially in
the case of extra-mammary Paget’s disease, where the
lesions are often large. Additionally, the disease primarily
affects older populations, not all of whom can tolerate
surgery. Thus, given the potential slow progression of the
disease, considerable interest in less invasive approaches
exists[8]. One such approach is photodynamic therapy
(PDT). PDT uses a photosensitizing agent that, when
activated by light of a particular wavelength, induces a
chemical reaction within the cells, destroying the affected
tissue[9,10]. Since the photosensitizing agent is more
readily absorbed by abnormal cells, healthy tissue is
spared. While topical photosensitizing agents are most
commonly used (Levulan
® Kerastick
® (a type of 5-ami-
nolevulinic acid or ALA) and Metvix
® (a type of methyl
aminolevulinate or MAL)), intravenously administered
versions (hematoporphyrin derivatives, such as porfimer
sodium) are also available[11].
The purpose of this project was to assess the clinical
effectiveness of PDT for mammary and extra-mammary
Paget’s disease, based on existing published, peer-
reviewed clinical studies.
Methods
A systematic review of relevant studies was undertaken
following Cochrane guidelines and the QUORUM state-
ment[12].
Identification of potentially relevant studies
To identify studies published as of February 2011, a
structured search strategy, which combined relevant
controlled vocabulary terms (Medical Subject Headings
(MeSH) in MEDLINE, and EMTREE thesaurus terms in
EMBASE) with additional non-index terms was first
developed. Such terms included photochemotherapy,
photosensitizing agent(s), photodynamic therapy or
PDT, and Paget’s disease (both mammary and extra-
mammary). The search strategy was then applied to the
following electronic bibliographic databases: PubMed
(MEDLINE and non-MEDLINE), The Cochrane Library,
EMBASE, the UK Centre for Reviews and Dissemination
databases (DARE, HTA and NHS EED), CINAHL, Psy-
cINFO, and Web of Science. No date, language or other
limits were applied. Grey literature was also searched,
including guidelines and clinical trials web sites, confer-
ence proceedings, Google and checking the reference
lists of relevant articles. Full search details are provided
in Additional file 1.
Selection of studies for inclusion in the review
Two researchers independently screened the titles and
abstracts of citations identified through the literature
search using predetermined inclusion criteria (Table 1).
Corresponding papers of those deemed potentially rele-
vant were then retrieved for full review by the same two
researchers. Disagreements between them were resolved
through discussion and, if necessary, third party
adjudication.
Extraction of data from included studies
Information from included studies was systematically
extracted by two independent reviewers using a pre-
tested data abstraction form, accompanied by a set of
decision rules. The abstracti o nf o r mi n c l u d e de l e m e n t s
related to study setting, sample size, and design; com-
parator (where applicable); outcomes measured (both
cosmetic and clinical); and findings. Reviewers compared
results and discrepancies were, once again, resolved
through discussion and, if necessary, third party
adjudication.
Critical appraisal of included studies
Studies were appraised using the Oxford Centre for Evi-
dence-based Medicine Levels of Evidence and Grades of
Recommendation[13].
Data analysis and synthesis of results
Data extracted from studies were summarized in tabular
form to facilitate qualitative analyses of trends or patterns
in the findings. Where possible, weighted pooled means
for outcomes, such as percentage of patients who experi-
enced complete eradication of lesions were also calcu-
lated in order to generate summary point estimates.
Results
Results of the literature search are shown in Figure 1. Of
140 papers initially identified (after removing duplicates),
34 Paget’s papers were retrieved for full review and 32
initially met the inclusion criteria. Two of the 32 papers
that met the inclusion criteria were excluded because
appropriate outcomes could not be obtained: 1 study was
a cohort of patients with skin lesions who were treated
with PDT that included one patient with EMPD whose
individual treatment outcomes could not be determined
from the report[5] and the other study was a review of
cases in a vulval Paget’s disease patient registry that
included two patients treated with PDT whose individual
treatment outcomes could not be determined from the
report[14]. Six of the 32 papers that met the inclusion
criteria were further excluded because patients had
already been included in other studies. Additionally, two
papers reported duplicate data, resulting in 24 papers of
23 studies included in the final review.
Description of included studies
The 23 studies comprised single-centred case reports of
1-2 patients (9) and case series of 1-16 patients (14)
Nardelli et al. BMC Dermatology 2011, 11:13
http://www.biomedcentral.com/1471-5945/11/13
Page 2 of 7carried out in China (7), Japan (4), Korea (3), UK (2), US
(2), Austria (1), Italy (1), Belgium (1), Israel (1), and Brazil
(1) (Table 2). Collectively, they involved 102 patients (34
female, 51 male, 17 unspecified gender), ranging in age
from 28 to 92 years (majority over 50 years), and 136
lesions treated with PDT. Of the 102 patients, the major-
ity had extra-mammary Paget’s disease (88). Among the
remaining 14, 3 had mammary Paget’sd i s e a s ea n d1 1
were unspecified. Most studies excluded invasive or
metastasized EMPD; 3 patients in 3 studies had an
underlying carcinoma and/or lymphatic involvement.
Only a few studies reported the Fitzpatrick skin type of
included patients: in 1 study, all 16 patients were Fitzpa-
trick skin type IV or V (Asian)[15] and in another, 7 of 8
patients included were skin type I or II and 1 patient was
type III[11,16]. Four studies reported the race of patients,
3 studies with 12 patients, all Caucasian[1,17,18] and a
case report on one Chinese patient[3]. In patients with
extra-mammary Paget’s disease, the majority of lesions
appeared in the groin/pubis/genitalia, regardless of gen-
der (female: 28 lesions; male: 47 lesions) and in the peria-
nal region in females (15 lesions). Across all lesion types,
approximately one third (44/136) had received prior
treatment (including mainly surgical and/or laser exci-
sion (37); topical ALA-PDT (4), cryotherapy (1), topical
imiquimod (1), and irradiation and chemotherapy (1)).
Heterogeneity in PDT treatment regimens between stu-
dies existed, however PDT was typically performed with
topical 5-ALA or m-ALA, or intravenous hematopor-
phyrin derivatives activated by red light either in the
form of visible light or laser. The number of PDT treat-
ments per lesion ranged from1 to 10, with the majority of
lesions receiving 1-3 treatments. Descriptions of each
study are presented in Additional file 2.
Quality of included studies
Based on the Oxford Centre for Evidence-based Medi-
cine Levels of Evidence, the quality of the studies was
low. All except 2 were retrospective and all were non-
comparative and small in sample size. In general, study
design was attributed to the rarity of the condition.
Safety
Half of the included studies reported adverse events.
Across these studies, adverse events appeared mild and
transient and included mainly local pruritus, erythema,
swelling, blistering, effusion, superficial erosions, crust
formation and/or peeling[4,15-17,19-21]. Local photo-
toxicity/photosensitivity was also reported in all patients
in 2 studies (n = 7 and n = 1)[17,21]. Treatment-related
pain was commonly experienced[15,17,18,20,22] and in
1 prospective study (16 patients) ranged from 2-10
(mean ± SD: 5.4 ± 1.3) on a VAS scale (0-none, 10-
extreme), with patients with perianal and vulval lesions
rating pain higher than those with axillary or scrotal
lesions[15]. The single study that assessed liver function
post treatment with PDT reported normal values[23].
Clinical effectiveness
An assessment of clinical effectiveness included response
of lesion to treatment (may include lesion recurrence)
reported by all 23 studies, and cosmetic or anatomical
Table 1 PICOS Elements of the Review Protocol
Parameter Inclusion Criteria Exclusion Criteria
Participants ● Studies of participants diagnosed with Paget’s disease (mammary or extramammary, invasive or
non-invasive) and 18 years of age or older
● Studies of participants under
18 years of age
Intervention ● Any application of a photodynamic therapy alone or in conjunction with another therapy
● All wavelengths and light sources will be considered
● Any formulation of ALA, including experimental formulations
● MAL
● All intravenous photosensitizers
● None
Comparator ● All studies with or without comparators
Outcomes ● Any clinical outcome, including (but not restricted to): complete lesion eradication; cosmetic
results; patient satisfaction; adverse effects and the need for additional therapy




● Any study design including case series and case reports ● Review articles
● Economic evaluations
● Editorials and opinion pieces
 
 
   
 
 
Total search results for Paget’s 
disease after duplicates were 
removed 
= 140 citations 
 
Titles and abstracts reviewed 








Figure 1 Literature search results and study selection for
clinical review of Paget’s Disease. *Two papers had reports of
duplicate patient data resulting in 24 papers and 23 included
studies overall.
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Individual lesion response outcomes for each study are
presented in Additional files 3 and 4.
Extra-mammary Paget’s disease (EMPD)
Lesion response
In 99 patients with a total of 133 extra-mammary
lesions, 77 of the lesions showed a complete response,
52 a partial response, and 4 a minimal or no response
to PDT. No difference in response patterns between
previously treated lesions and those that had received
no prior treatment was apparent.
Two of the 23 studies included were prospective case
series. One prospective study of 16 patients with 21
lesions reported a 66% (14/21) clinical complete
response rate after 3 topical ALA-PDT treatments and a
50% recurrence rate, dropping the complete response
rate to 33% (7/21) at 24 months[15]. The other
prospective study of 7 patients with 11 lesions found a
75% complete response rate 1-5 months after 3 topical
MAL-PDT treatments and did not report any longer
term outcomes[17].
Of 76 patients with 101 lesions from retrospective stu-
dies, 62 lesions demonstrated a complete response, 37 a
partial response and 2 minimal to no response to PDT.
No differences in response patterns across type of PDT
used were evident. Long-term (> 2 year) follow-up of
patients was reported in 2 of the 16 retrospective stu-
dies[8,11,16,20]. Of 5 lesions (in 4 patients) showing
complete responses after treatment with intravenous
porfimer sodium-PDT, 4 lesions remained recurrence
free 62-96 months after treatment and 1 lesion recurred
48 months after treatment[11,16,20]. A complete
response was also maintained (47 and 88 months after
treatment) in 2 lesions in a patient treated with topical
ALA-PDT[11,16].
Table 2 Characteristics of included studies
Study Country Diagnosis Age range (years) No. of patients No. of lesions
a
Prospective case series
Li et al. (2010)[15] China EMPD 54-83 16 21
Raspagliesi et al. (2006)[17] Italy EMPD 55-75 7 11
Retrospective case reports/case series
Housel et al. (2010)[16] & Shieh et al. (2002)[11] USA EMPD 50-75 8 24
Thaler et al. (2010)[25] Austria EMPD 69 1 1
Andretta-Tanaka et al. (2009)[1] Brazil EMPD 67-76 4 4
Fukui et al. (2009)[44] Japan EMPD 66-84 5 8
Li et al. (2009)[3] China EMPD 75 1 1












Liu et al. (2007)[4] China EMPD 64-80 5 5
T’kint & Roseeuw (2006)[45] Belgium EMPD 64 1 2
Kim et al. (2005)[46] Korea EMPD 54-73 7 NR
a
Madan et al.(2005)[21] UK EMPD 80 1 1
Mikasa et al. (2005)[47] Japan EMPD 73-92 2 NR
a
Tulchinsky et al. (2004)[8] Israel EMPD 49-74 2 NR
a
Zawislak et al. (2004)[18] UK EMPD 66 1 1
Zhu et al. (2004)[48] China PD
c NR 8 8
Song et al. (2003)[49] Korea EMPD 51-78 2 6






Chang et al. (2001)[50] Korea EMPD 50-73 7 8
Runfola et al. (2000)[20] USA EMPD 79 1 1
Henta et al. (1999)[22] Japan EMPD 74 1 1









Kubota et al. (1986)[51] Japan EMPD 77 1 1
Total: 23 studies 28-92 102 136
a
a total no. of lesions includes all lesions entering study; if a study did not report number of lesions it was assumed that each patient had 1 lesion
b age only reported for 2 of 4 patients
c unspecified Paget’s disease
EMPD = extra-mammary Paget’s disease, MPD = mammary Paget’s disease, NR = not reported
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Good cosmetic outcomes were demonstrated after PDT
in both of the prospective case series[15,17]. In the
study of 16 patients, 100% of the patients with a com-
plete response reported satisfaction with their cosmetic
outcomes[15]. In this study, investigator rated cosmetic
outcome was excellent or good in 36% (5/14) of the
lesions with incomplete responses and poor in 64% (9/
14) of the lesions. Reasons for a poor cosmetic outcome
included depigmentation (4), atrophy (2), redness (2)
and induration (1)[15]. An acceptable cosmetic outcome
with no scarring and no substantial changes in baseline
function or anatomic profile was reported in all patients
with a complete response in the other prospective study
[17].
In a retrospective case series of 8 patients, excellent
cosmetic outcomes with no scarring were reported in
the 5 patients treated with ALA-PDT[24]. Scarring was
reported in the 3 patients treated with porfimer-sodium
PDT, however the scarring was documented as less
severe than prior surgical scars[11]. No post-treatment
functional impairments were found in any of the 8
patients[11,24]. Several other case reports described pre-
served anatomical functionality and improvements in
patient comfort and quality of life after PDT[1,3,22,25].
Mammary Paget’s disease (MPD)
Lesion response
There are only three reports of the use of PDT for
MPD. One patient with a recurrent lesion after radical
mastectomy showed a complete response after treatment
with topical PDT[26]. No recurrence was reported for
this patient 12 months after treatment. No treatment
history, surgical description, or follow-up period were
specified for the other two patients, however both were
reported to have a complete responses after combined
surgical excision and topical PDT[19].
Cosmetic and/or functional response
No evidence was available regarding cosmetic and func-
tional outcomes after PDT for the treatment of MPD.
Discussion
This review aimed to assess the clinical effectiveness of
photodynamic therapy for the treatment of Paget’sd i s -
ease. Based on the limited quantity and quality of stu-
dies found, the use of PDT for Paget’s disease appears
safe and well tolerated. There were no reports of mor-
tality or significant adverse events related to PDT, how-
ever, rare complications may not be observed in these
small studies. Although a complete response following
PDT was achieved in approximately half of the 103
extra-mammary lesions, the durability of this response
remains unclear, since follow-up periods were typically
less than one year. Nevertheless, good cosmetic and
functional outcomes were demonstrated and, in general,
patients appeared satisfied with PDT. Evidence of the
short and long term effectiveness of PDT for MPD was
limited, with only 3 case reports included in the review.
While PDT yielded complete responses in all 3 cases, 1
of the 3 had received previous surgical treatment and
the other 2 had received PDT combined with surgery.
It has been suggested that the effectiveness of PDT
may depend on several factors, such as lesion location,
presence or absence of underlying carcinomas and
patient skin type[1,7,15,27,28]. In the studies included in
this review, no trends associated with these factors
emerged.
The standard treatment for EMPD is surgical excision,
which is often extensive, involving large margins and
reconstructive surgery. Also, it is frequently associated
with anatomical and functional impairments[7,17,29].
Histologically, Paget’s disease typically extends beyond
the visible lesion present, making it difficult to obtain a
complete excision[7,29]. Consequently, high recurrence
rates after surgery for EMPD have been shown (studies
report approximately 30 to 70% of lesions recur after
treatment)[1,7,27,30-32]. Patients with in-situ EMPD are
less likely to show recurrences (~35% of lesions) in
comparison to patients with invasive EMPD (up to 67%
of lesions)[27,33]. Although no comparative studies of
PDT were found, other treatment options exist. For
example, Moh’s micrographic surgery has been asso-
ciated with lower recurrence rates (8-28%), as well as
less morbidity compared to standard surgical excision
[1,30-32,34]. Laser therapy, radiotherapy and/or systemic
chemotherapy, topical pharmacotherapies (imiquimod or
5-FU) and cryotherapy have also been used. Recent stu-
dies of carbon dioxide (CO2) laser treatment of EMPD
lesions report recurrence rates similar to those following
surgical excision (~30-70%) but also significant pain
[27,35]. Radiotherapy can be used as a primary treat-
ment or as an adjuvant treatment after surgical excision
[36]. Recurrence rates from 0 to 60% have been
reported, with no apparent differences between use as a
primary treatment or as a postoperative adjuvant[37-39].
Systemic chemotherapy applied in combination with
radiotherapy appears to improve responses and prevent
recurrences, but the use of systemic chemotherapy,
alone, requires further investigation[27]. Comparable
response rates with no subsequent recurrences after the
use of imiquimod cream for the treatment of non-inva-
sive EMPD in a small number of cases with short fol-
low-up periods have been demonstrated[1,40]. However,
in a larger case series, treatment of EMPD with imiqui-
mod resulted in poor response rates (38%)[39]. Little
evidence on the use of cryotherapy to treat EMPD
exists; therefore, it is unclear whether it offers a suitable
primary treatment option.
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presence or absence of underlying breast cancer) is a
mastectomy with or without lymph node removal[41].
Mastectomy alone (regardless of lymphatic removal) for
the treatment of in situ lesions has demonstrated 5-year
recurrence free survival rates of 90% however, recur-
rence free survival drops to 63% in patients with under-
lying invasive carcinomas[42]. Adjuvant chemotherapy
and/or radiation may be used to decrease recurrences
[41]. Other more breast conserving treatment options
include excision of the nipple, lumpectomy and radia-
tion alone however, when used to treat patients with
underlying breast cancer, these approaches may be asso-
ciated with high recurrence rates[2,41]. Local excision
combined with radiation has been shown to be a highly
effective treatment for MPD without underlying breast
cancer with high rates of long-term disease-free survival,
showing 11% recurrence rates in a long-term, collabora-
tive, multi-centre study[43].
With the limited amount and low level of evidence
available, definitive conclusions on the use of PDT for
the treatment of Paget’s disease are not possible. How-
ever, given the significant morbidity associated with sur-
gery and the frequency of recurrence associated with
alternate treatment options, PDT for primary or recur-
rent EMPD appears promising and warrants further
comparative investigation. In the rare case of MPD
without underlying breast cancer, PDT may offer a
breast-conserving treatment option or an adjuvant to
surgery. While given the rarity of this disease, rando-
mized controlled trials may not be feasible, comparative
data could be collected through a prospective, interna-
tional registry.
Conclusions
No evidence on the comparative effectiveness of PDT
for the treatment of Paget’s disease is available. How-
ever, existing non-comparative studies suggest PDT
offers a promising less-invasive alternative worthy of
further investigation as a primary or adjuvant treatment
option, especially given the significant morbidity asso-
ciated with the standard treatment option (surgical
excision).
Additional material
Additional file 1: Literature search. Details of the literature search
strategy and search results are provided in additional file 1.
Additional file 2: Table of included studies of photodynamic
therapy (PDT) for Paget’s disease. Details of study and patient
characteristics, interventions, outcomes and quality of included studies
are provided in additional file 2.
Additional file 3: Studies of photodynamic therapy (PDT) for
Extramammary Paget’s disease: lesion response. Details of individual
patient and lesion characteristics, type and number of PDT treatments,
lesion response outcomes and lengths of follow-up are provided in
additional file 3.
Additional file 4: Studies of photodynamic therapy (PDT) for
Mammary Paget’s disease: lesion response. Details of individual
patient and lesion characteristics, type and number of PDT treatments,
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